Actos News
Jury hearing arguments in Actos bladder cancer lawsuit
The first Actos bladder cancer lawsuit trial is underway in California, where a jury is hearing arguments from a patient who developed bladder cancer after using the diabetes medication. Jack Cooper took Actos for two years before developing bladder cancer. More »
Takeda to release successor to Actos
Takeda Pharmaceuticals plans to release a successor to controversial type II diabetes drug Actos in mid- 2013. The drug, known by its medical name alogliptin, was previously twice denied approval by the Food and Drug Administration for insufficient health data concerning potential side effects. More »
Hissey Kientz publishes frequently asked questions for Actos bladder cancer
Hissey Kientz law firm has published a frequently asked questions section to provide more information about the diabetes medication Actos and bladder cancer to readers. The FAQs include information concerning who should not take Actos and certain risks associated with the drug. More »
Judge allows company to sell generic Actos
A U.S. District Judge has allowed a company to begin immediately selling generic Actos, despite resistance from the Food and Drug Administration (FDA). Watson Pharmaceuticals will begin marketing the generic version of the top-selling type II diabetes drug Actos, which has come under fire for health concerns. More »
Actos doubles bladder cancer risk, British study finds
A new study has confirmed that the diabetes medication Actos doubles the risk of developing bladder cancer among people who use the drug for at least two years. The Canadian study was published in the British Medical Journal (BMJ) and included more than 115,000 diabetes patients that were treated between 1988 and 2009. More »
Whistleblower lawsuit alleges financial conflicts in Avandia, Actos research
A whistleblower lawsuit filed against Takeda Pharmaceuticals alleges that there were financial conflicts between the company and a doctor performing research on the diabetes drugs Actos and Avandia. Dr. Helen Ge’s lawsuit claims that the connection between the company and Dr. Steven Nissen should be carefully considered when analyzing Actos’ safety risks compared with those of Avandia. More »
Actos linked to higher bladder cancer risk, health agency says
Health Canada—the country’s health regulator—has issued a statement warning that patients who used the type II diabetes drug Actos for more than one year are at an increased risk of bladder cancer. The agency is requiring manufacturer Takeda Pharmaceuticals to immediately update the drug’s label to reflect the increased risk. More »
Whistleblower claims Actos maker hid heart failure data
A whistleblower lawsuit has alleged that the manufacturer of the diabetes medication Actos failed to accurately report cases of heart failure associated with the drug to the Food and Drug Administration. Helen Ge’s Actos lawsuit alleges that Takeda Pharmaceuticals attempted to downplay risks associated with the drug by underreporting and misclassifying adverse side effects. More »
Illinois man files Actos bladder cancer lawsuit
An Illinois man has filed an Actos bladder cancer lawsuit against the manufacturer of the diabetes drug. William Greenlee alleges in his lawsuit that Takeda Pharmaceuticals failed to properly warn patients of the increased risks of bladder cancer when taking Actos for more than a year. More »
Diabetes drugs Byetta, Januvia linked to cancer risk
A new study has found that diabetes patients taking the drugs Januvia or Byetta may be three times more likely to develop pancreatitis or pancreatic cancer. Researchers also discovered a possible increased risk of thyroid cancer among Byetta users. More »